Filing Flows › Sunshine Biopharma (SBFM) › Q2 2026 › vs Q1 2026
Sunshine Biopharma (SBFM) Q2 2026 vs Q1 2026 (quarter over quarter)
Sunshine Biopharma's revenue rose $1.2M (+15%) from $8.1M in Q1 2026 to $9.3M in Q2 2026.
Sunshine Biopharma, Q2 2026: revenue $9.3M (-2% year over year), operating margin -17.4%, net loss $1.6M, operating cash flow −$918K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.3M | $8.1M | $1.2M | +15% |
| Other income, net | $49K | $152K | −$103K | -68% |
| Net loss | $1.6M | $1.2M | $320K | +26% |
| Costs & expenses | $10.9M | $9.5M | $1.4M | +15% |
| Operating costs | $10.9M | $9.5M | $1.4M | +15% |
| Cost of revenue | $6.8M | $5.9M | $929K | +16% |
| Operating expenses | $4.0M | $3.6M | $463K | +13% |
| Operating cash sources | $1.6M | $1.2M | $320K | +26% |
| Depreciation & amortization | $78K | $77K | $1K | +1% |
| Working capital & other | $568K | −$905K | $1.5M | — |
| Cash used in operations | $918K | $2.1M | −$1.2M | -56% |
| Net loss absorbed | $1.6M | $1.2M | $320K | +26% |
Questions
How much did Sunshine Biopharma's revenue grow quarter over quarter in Q2 2026?
Sunshine Biopharma's revenue rose $1.2M (+15%) from $8.1M in Q1 2026 to $9.3M in Q2 2026.